Status:
COMPLETED
Effectiveness of "Medisinstart"
Lead Sponsor:
Apokus AS
Collaborating Sponsors:
Norwegian Pharmacy Association
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition. It is based on resea...
Eligibility Criteria
Inclusion
- First time prescription for a drug belonging to one of the following groups (ATC-code):
- Dabigatran etexilate (B01AE07)
- Rivaroxaban (B01AF01)
- Apixaban (B01AF02)
- Beta blocking agents (C07)
- Calcium channel blockers (C08)
- Agents acting on the renin-angiotensin system (C09)
- HMG CoA reductase inhibitors (statins) (C10AA)
Exclusion
- Prior use (within the last 3 years) of the drug in question independent of strength, dose and formulation
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
1480 Patients enrolled
Trial Details
Trial ID
NCT02261402
Start Date
October 1 2014
End Date
December 1 2017
Last Update
July 20 2021
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Apotek 1 Alta
Alta, Norway
2
Apotek 1 Andselv
Andselv, Norway
3
Boots apotek Harebakken
Arendal, Norway
4
Sykehusapoteket Arendal
Arendal, Norway